FDA Approves Subcutaneous Isatuximab-irfc - Takeaways - MDSpire

FDA Approves Subcutaneous Isatuximab-irfc

The approval expands subcutaneous use across newly diagnosed and previously treated multiple myeloma.

  • By

  • Kathryn Wighton

  • July 10, 2026

  • 2 min

Share

  • 1

    The FDA approved subcutaneous isatuximab-irfc for three indications in adult patients with multiple myeloma.

  • 2

    Isatuximab-irfc is approved with pomalidomide and dexamethasone for patients with prior therapy including lenalidomide.

  • 3

    The drug is also approved with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.

  • 4

    For newly diagnosed multiple myeloma patients not eligible for stem cell transplantation, it is approved with bortezomib, lenalidomide, and dexamethasone.

  • 5

    The recommended dose is 1,400 mg subcutaneously, with warnings for hypersensitivity, neutropenia, and other risks.

Original Source(s)

FDA Approves Subcutaneous Isatuximab-irfc

  • by Kathryn Wighton

  • July 10, 2026

Related Content

SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk

A Korean cohort study found fewer kidney cancer cases among patients with type 2 diabetes who initiated sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors.

FDA Approves Treg Cell Therapy

A randomized clinical trial found higher chronic GVHD-free survival and lower rates of serious chronic GVHD compared with standard transplantation in adults with blood cancers.

Side Effects: Bro Science, Actually

Creatine's ATP-buffering trick isn't just for biceps. In mice, it juices up dendritic cells' energy supply, sharpening T-cell priming and shrinking tumors on daily injections. Human DCs got the memo too, at least in a dish. Early days, but a fun plot twist for gym-bag chemistry.